Integrated Filing

DIPNA PHARMACHEM LIMITED CIN:L24100GJ2011PLC066400 Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad - 380 055 E-mail: dharachem99@yahoo.in Date: 4th November, 2026 BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai -400 001. Dear Sir / Madam, Subject: Integrated Filing (Finance) for the Quarter ended on 30th June, 2026 Ref: Symbol: DPL/ Code: 543594 Pursuant to the Securities and Exchange Board of India Circular No SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024, please find attached the Integrated Filing (Financial) Quarter ended 30th June, 2026. Kindly take the same on your record and oblige us. Thanking You For, Dipna Pharmachem Limited Keyur Dipakkumar Shah Managing Director DIN: 03167258 A. Unaudited Financial Result DIPNA PHARMACHEM LIMITED CIN : L24100GJ2011PLC066400 Reg. Address: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, Gujarat, India, 380055 Email Id :-dharachem99@yahoo.in STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE THREE MONTHS ENDED ON 30TH JUNE, 2026 (Amount Rs. In lakhs) Quarter ended Year to date Year ended Sr.No Particulars June 30, 2026 March 31, 2026 June 30, 2025 June 30, 2026 June 30, 2025 March 31, 2026 IUnauditedl IAuditedl IUnaudltedl IUnaudltedl IUnauditedl !Audited! 1 Income Revenue from operations a. Sale of Products and Services 2,033.03 202.49 18S0.04 2,033.03 1,850.04 12,908.33 b. Other operating Income 346.03 2.54 346.03 2.54 Other Income Total Income 2,379.06 205.03 1,850.04 2.379.06 1,850.04 12,910.87 2 Expenses a. Purchase of stock-in-trade 1,890.28 1,354.20 1,872.02 1,890.28 1,872.02 12,237.20 b. Changes In Inventories of finished goods, work-In-progress and stock-in-trade 7.63 (1,542.76) (421.21) 7.63 (421.21) (1,489.05) c. Employee benefits expense 8.80 10.37 7.97 8.80 7.97 41.12 d. Finance costs 30.54 23.14 16.06 30.54 16.06 146.32 e. Depreciation and amortization expense 0.41 0.44 0.41 1.43 f. Other expenses 387.37 336.98 318.02 387.37 318.02 1,614.90 g. Power and Fuel 1.61 0.38 0.16 1.61 0.16 4.47 Total Expenses 2,326.64 182.75 1,793.02 2,326.64 1,793.02 12,556.39 3 Profit before U:ceptlonal Items and tax (1-2) 52.42 22.28 57.02 52.42 57.02 354.48 4 Exceptional items 5 Profit before tax (3-4) 52.42 22.28 57.02 52.42 57.02 354.48 6 Tax expense a. Current Tax 13.00 4.77 13.00 91.66 b. Deferred Tax 10.351 10.37 Total Tu Expense 13.00 4.42 13.00 91.29 7 Net proflt/(Loss) for the period (5-6) 39.42 17.86 57.02 39.42 57.02 263.19 8 Other Comprehensive Income Item that will not be reclasslfled to profit or loss (net of tax) 9 Total Comprehensive Income (after taJces) (7+8) 39.42 17.86 57.02 39.42 57.02 263.19 10 Paid up equity share capital (Face value of Rs.10/· each} 2,628.92 2,628.92 2,404.53 2,628.92 2,404.53 2,628.92 11 Other equity (Reserves) 1,813.80 1,774.39 1,501.77 1,813.80 1,501.77 1,774.39 12 Earning per equity share a.Basic 0.15 0.07 0.24 0.15 0.24 1.00 b.Oiluted 0.15 0.07 0.24 0.15 0.24 1.00 Notes: 1. Number of Investors complaints received, disposed of and lying unresolved as on 30.06.2026: Nil 2. The above results have been reveiwed by audit committee and approved by the Board of Directors at their meeting held on 4th November, 2026 3. Previous year figures have been regrouped/ reclassified wherever necessary to confirm to the current financial year figures and as per Schedule Ill 4. The Company does not have any subsidiary company. 5. Beginning April 1, 2025, the Company has, for the first time adopted IND AS with transition date of April 1, 2024 and accordingly the above audited Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards} Rules, 2015 (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules Issued there under. 6. As the Company is having only one segment I.e. Chemicals Segment, there are no reportable segment in accordance with the requirement of Accounting Standard (As-17) "Segment Reporting" specified under Section 133 of the Companies Act, 2013. 7. There was no adjustment in the profit & loss for Ql (F.Y. 2026-27) under IND AS. For, Dlpna Pharmachem Limited Place : Ahmedabad _.... ... , Managing Director Date: 4th November, 2026 ~-i. DIN: 03167258 DEVADIYA & ASSOCIATES CHARTERED ACCOUNTANTS Independent Auditor's Review Report on the quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Board of Directors of Dipna Pharmachem Limited We have reviewed the accompanying statement of unaudited financial results of DIPNA PHARMACHEM LIMITED (PAN: AADCD9404F) for the period ended 30th June, 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter. For Devadiya & Associates Chartered Accountants FR NO: 1230 W Place: Ahmedabad Date: 04/11/2026 A-301, The First, B/h ITC Narmada Hotel, Vastrapur, Ahmedabad 380015. Voice:-079-40326703, 079-40076183 Email:-info@devadiya.com Web.:-www.devadiya.com. Offices at:-Ahmedabad, Baroda & Banswara DIPNA P.HARMACHEM LIMITED CIN:L24100GJ2011PLC066400 Regd. Office: A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad - 380 055 E-mail: dharachem99@yahoo.in B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: - Not Applicable C. Format for Disclosing Outstanding Default on Loans and Debt Securities: - Not Applicable as there is no default in the payment of outstanding Loans / revolving facilities, unlisted debt securities. D. Format for Disclosure of Related Party Transactions (Applicable only for half-yearly filings i.e., znd and 4th quarter): - Not Applicable E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along-with Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable only for Annual Filing i.e 4th Quarter): - NotApplicable